Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07222709 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult Participants

StatusActive, Not Recruiting
PhasePhase 1
SponsorAbbVie
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later May 2026 → Sep 2026
See other at-risk trials from AbbVie

Record History

  1. Completion pushed from Sep 2026 to Nov 2026 Primary completion date changed from estimate of Sep 2026 to Sep 18, 2026 Show 1 more changeShow less
    • Primary completion date changed from estimate of Sep 2026 to Sep 18, 2026
  2. Primary endpoints: details revised at 1 of 12 entries Enrollment closed, study ongoing · Primary and study completion pushed from May 2026 to Sep 2026 · Site details revised · 1 more Show 4 more changesShow less
    • Enrollment closed, study ongoing
    • Primary and study completion pushed from May 2026 to Sep 2026
    • Site details revised
    • Eligibility criteria expanded, about 5 words
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AbbVie
345 trials monitored
See 27 trials at risk
This study will assess the adverse events, tolerability, and how oral ascending doses of ABBV-1042 moves through the body of healthy adult participants.
Trial Details
NCT Number NCT07222709
Lead Sponsor AbbVie
Conditions Healthy Volunteer
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov